Events2Join

Caroline J Loew


Caroline Loew, Ph.D. - Mural Oncology

Caroline Loew, Ph.D. is the chief executive officer of Mural Oncology. Dr. Loew's biopharmaceutical career spans more than 25 years of drug development and ...

Caroline J Loew, PhD - Cambridge, Massachusetts, United States

Location: Cambridge · 500+ connections on LinkedIn. View Caroline J Loew, PhD's profile on LinkedIn, a professional community of 1 billion members.

Caroline J Loew - Speaker - Pennsylvania Conference for Women

Caroline J Loew is the head of R&D strategy and planning at Bristol-Myers Squibb, joining the company in December 2015.

Caroline J Loew, PhD on LinkedIn: Developing new drugs is hard ...

Developing new drugs is hard, and many of us have been bruised by the process. But those lessons are important, and for me they crystallized ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

Loew , Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public ...

Ep. 50 - Caroline J. Loew, Chief Executive Officer of Glympse Bio

Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered, and integrated teams.

Caroline J Loew - Chief Executive Officer Designate @ Mural ...

Caroline J Loew is the current Chief Executive Officer Designate of Mural Oncology. She previously worked at Glympse Bio as a Strategic Advi...

Caroline J Loew, Mural Oncology PLC: Profile and Biography

Caroline J Loew is Chief Executive Officer at Mural Oncology PLC. See Caroline J Loew's compensation, career history, education, & memberships.

Caroline J. Loew - MURA | Mural Oncology PLC - Wall Street Journal

Caroline J. Loew holds the position of Chief Executive Officer, Secretary & Director at Mural Oncology Plc.

Caroline J Loew: We're excited to launch Mural Oncology - OncoDaily

Caroline J Loew: We're excited to launch Mural Oncology / cancer, Caroline J Loew, immuno-oncology, Mural Oncology, nemvaleukin, OncoDaily, ...

Caroline J Loew - CEO at Mural Oncology - The Org

Caroline J Loew, PhD is currently the CEO of Mural Oncology. Previously, Caroline J served as a Strategic Advisor | Consultant and President and CEO at Glympse ...

Delivering The Next Evolution In Immuno-Oncology

By Caroline J. Loew, Ph.D., CEO of Mural Oncology. Caroline Loew. Cancer is one of the most complex and dynamic human diseases.

Interview with Glympse Bio CEO Caroline Loew - YouTube

Glympse Bio https://glympsebio.com/ CEO Caroline Loew tells what it's like to lead a high-profile spinout from MIT, reflects on her time at ...

Why a former BMS exec calls her new CEO role 'unfinished ...

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she's building a new company culture at an Alkermes spinoff ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc. PR Newswire - Thu ...

Read News and Stories about Caroline J Loew - Oncodaily

Caroline J Loew · ESMO 2024 Congress. September 13-17, 2024 · ASCO Annual Meeting. May 30 - June 4, 2024 · Yvonne Award 2024. May 31, 2024 · OncoThon 2024, Online.

Glympse Bio, Inc. Appoints Caroline J Loew, Ph.D. President and ...

Glympse Bio, Inc. Appoints Caroline J Loew, Ph.D. President and Chief Executive Officer ... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Glympse Bio, Inc. a ...

Caroline Loew: Positions, Relations and Network - MarketScreener

Profile. Caroline J. Loew is currently the President, Chief Executive Officer & Director at Mural Oncology Plc. Previously, she held the ...

Glympse Bio CEO and Key Executive Team - Craft.co

Glympse Bio's Director, President & Chief Executive Officer is Caroline J. Loew. Other executives include Wendy Winckler, Chief Scientific Officer; ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track ...